A depressive endophenotype of mild cognitive impairment and Alzheimer's disease

Leigh A Johnson, James R Hall, Sid E O'Bryant, Leigh A Johnson, James R Hall, Sid E O'Bryant

Abstract

Background: Alzheimer's disease (AD) is a devastating public health problem that affects over 5.4 million Americans. Depression increases the risk of Mild Cognitive Impairment (MCI) and AD. By understanding the influence of depression on cognition, the potential exists to identify subgroups of depressed elders at greater risk for cognitive decline and AD. The current study sought to: 1) clinically identify a sub group of geriatric patients who suffer from depression related cognitive impairment; 2) cross validate this depressive endophenotype of MCI/AD in an independent cohort.

Methods and findings: Data was analyzed from 519 participants of Project FRONTIER. Depression was assessed with the GDS30 and cognition was assessed using the EXIT 25 and RBANS. Five GDS items were used to create the Depressive endophenotype of MCI and AD (DepE). DepE was significantly negatively related to RBANS index scores of Immediate Memory (B=-2.22, SE=.37, p<0.001), visuospatial skills (B=-1.11, SE=0.26, p<0.001), Language (B=-1.03, SE=0.21, p<0.001), Attention (B=-2.56, SE=0.49, p<0.001), and Delayed Memory (B=-1.54, SE = 037, p<0.001), and higher DepE scores were related to poorer executive functioning (EXIT25; B=0.65, SE=0.19, p=0.001). DepE scores significantly increased risk for MCI diagnosis (odds ratio [OR] = 2.04; 95% CI=1.54-2.69). Data from 235 participants in the TARCC (Texas Alzheimer's Research & Care Consortium) were analyzed for cross-validation of findings in an independent cohort. The DepE was significantly related to poorer scores on all measures, and a significantly predicted of cognitive change over 12- and 24-months.

Conclusion: The current findings suggest that a depressive endophenotype of MCI and AD exists and can be clinically identified using the GDS-30. Higher scores increased risk for MCI and was cross-validated by predicting AD in the TARCC. A key purpose for the search for distinct subgroups of individuals at risk for AD and MCI is to identify novel treatment and preventative opportunities.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Alzheimer’s Association (2012) Alzheimer’s Disease Facts and Figures. Alzheimers Dement 8: 1-72. doi:. PubMed: .
    1. Alzheimer’s Association (2008) 2008 Alzheimer’s disease facts and figures. Alzheimers Dement 4: 110-133. doi:. PubMed: .
    1. Alzheimer’s Association (2010) Changing the trajectory of Alzheimer’s disease. Facts and Figures.
    1. Gottesman II, Shields J (1973) Genetic theorizing and schizophrenia. Bri J Psychiatry 122: 15-30. doi:. PubMed: .
    1. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636-645. doi:. PubMed: .
    1. O’Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB et al. (2010) Decreased C-reactive protein levels in alzheimer disease. J Geriatr Psychiatry Neurol 23: 49-53. doi:. PubMed: .
    1. O’Bryant SE, Xiao G, Barber R, Reisch J, Doody R et al. (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67: 1077-1081. doi:. PubMed: .
    1. O’Bryant SE, Hobson VL, Hall JR, Barber RC, Zhang S et al. (2010) Serum Brain-Derived Neurotrophic Factor Levels Are Specifically Associated with Memory Performance among Alzheimer’s Disease Cases. Dement Geriatr Cogn Disord 31: 31-36. PubMed: .
    1. Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Liesinger AM et al. (2012) Neuropathologically defined subtypes of Alzheimer’s disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 124(5): 681-692. doi:. PubMed: .
    1. Braskie MN, Ringman JM, Thompson PM (2011) Neuroimaging measures as endophenotypes in Alzheimer’s disease. Int J Alzheimers Dis 2011: 490140:. PubMed: 21547229
    1. During EH, [!(surname)!], Elahi FM, Mosconi L, de Leon MJ (2011) The concept of FDG-PET endophenotype in Alzheimer’s disease. Neurol Sci 32: 559-569. doi:. PubMed: .
    1. Nilufer T (2011) Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer’s disease. Mol Neurodeg 3: 1-14. PubMed: .
    1. Cruchaga C, Kauwe J, Nowotny P, Bales K, Pickering EH et al. (2012) Cerebrospinal fluit APOE levels: an endophenotype for genetic studies for Alzheimer’s disease. Hum Mol Gene21 (20):4558-4571
    1. Panza F, Seripa D, D’Onofrio G, Frisardi V, Solfrizzi V et al. (2011) Neuropsychiatric symptoms, endophenotypes and syndromes in late-onset Alzheimer’s disease: Focus on APOE gene. Int J Alzheimers Dis, 2011. Article ID: 721457: 14 pages PubMed: 21559196
    1. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63: 530-538. doi:. PubMed: .
    1. Bruce JM, Bhalla R, Westervelt HJ, Davis J, Williams V et al. (2008) Neuropsychological correlates of self-reported depression and self-reported cognition among patients with mild cognitive impairment. J Geriatr Psychiatry Neurol 21: 34-40. doi:. PubMed: .
    1. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K (2006) Depressive symptoms, vascular disease, and mild cognitive impairment: Findings from the cardiovascular health study. Arch Gen Psychiatry 63: 273-280. doi:. PubMed: .
    1. Modrego PJ, Ferrández J (2004) Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: A prospective cohort study. Arch Neurol 61: 1290-1293. doi:. PubMed: .
    1. Hart RP, Kwentus JA, Taylor JR, Harkins SW (1987) Rate of forgetting in dementia and depression. J Consult Clin Psychol 55: 101-105. doi:. PubMed: .
    1. Baune BT, Suslow T, Engelien A, Arolt V, Berger K (2006) The association between depressive mood and cognitive performance in an elderly general population - the MEMO Study. Dem Geriatr Cog Dis 22: 142-149. doi:.
    1. Boone KB, Lesser IM, Miller BL, Wohl M, Berman N et al. (1995) Cognitive functioning in older depressed outpatients: Relationship of presence and severity of depression to neuropsychological test scores. Neuropsychol 9: 390-398. doi:.
    1. Kizilbash AH, Vanderploeg RD, Curtiss G (2002) The effects of depression and anxiety on memory performance. Arch Clin Neuropsychol 17: 57-67. doi:. PubMed: .
    1. Delano-Wood L, Houston WS, Emond JA, Marchant NL, Salmon DP et al. (2008) APOE genotype predicts depression in women with Alzheimer’s disease: A retrospective study. Int J Geriatr Psychiatry 23: 632-636. doi:. PubMed: .
    1. Lyketsos CG, Steele C, Baker L, Galik E, Kopunek S et al. (1997) Major and minor depression in Alzheimer’s disease: Prevalence and impact. J Neuropsychiatry Clin Neurosci 9: 556-561. PubMed: .
    1. González-Salvador T, Lyketsos CG, Baker A, Hovanec L, Roques C et al. (2000) Quality of life in dementia patients in long-term care. Int J Geriatri Psychiatry 15: 181-189. doi:. PubMed: .
    1. O’Bryant SE, Zhang Y, Owen D, Cherry B, Ramirez V et al. (2009) The Cochran County Aging Study: Methodology and Descriptive Statistics. Texas: Public Health; Journal 61: 5-7
    1. O’Bryant SE, Hall JR, Cukrowicz KC, Edwards M, Johnson LA et al. (2011) The differential impact of depressive symptom clusters on cognition in a rural multi-ethnic cohort: A Project FRONTIER study. Int J Geriatri Psychiatry 26: 199-205. doi:.
    1. O’Bryant SE, Edwards M, Menon CV, Gong G, Barber R (2011) Long-term low-level arsenic exposure is associated with poorer neuropsychological functioning: A Project FRONTIER Study. Int J Environ Res Public Health 8: 861-874. doi:. PubMed: .
    1. Gong G, Hargrave KA, Hobson V, Spallholz J, Boylan M et al. (2011) Low-level groundwater arsenic exposure impacts cognition: A project FRONTIER study. J Environ Health 74: 16-22. PubMed: .
    1. Johnson LA, Hobson V, Jenkins M, Dentino A, Michael Ragain R et al. (2011) The influence of thyroid function on cognition in a sample of ethnically diverse, rural-dwelling women: A project frontier study. J Neuropsychiatry Clin Neurosci 23: 219-222. doi:. PubMed: .
    1. Johnson LA, Mauer C, Jahn D, Song M, Wyshywaniuk L et al. (2013) Cognitive differences among depressed and non-depressed MCI participants: A Project FRONTIER study. Int J Geriatri Psychiatry 28(4): 377-382. doi:. PubMed: .
    1. O’Fallon LD, Dearry A (2001) Commitment of the National Institute of Environmental Health Sciences to Community-Based Participatory Research for Rural Health. Environ Health Perspect 109: 469-473. doi:. PubMed: .
    1. McKhann D, Drockman D, Katzman Folstein M R, Price D, et al (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group. Neurologist 34: 939-944
    1. Petersen RC, editor (2003) Mild Cognitive Impairment: Aging to Alzheimer’s Disease. New York: Oxford University Press.
    1. Ivnik R, Malec JF, Smith GE, Tangalos EG, Petersen RC et al. (1992) Mayo’s Older Americans Normative Studies: WAIS-R norms for age 56 to 97. Clin Neuropsychol 6: 1-30. doi:.
    1. O’Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L et al. (2008) Staging dementia using clinical dementia rating scale sum of boxes scores: A Texas Alzheimer’s Research Consortium study. Arch Neurol 65: 1091-1095. doi:. PubMed: .
    1. O’Bryant SE, Xiao G, Barber R, Reisch J, Hall J et al. (2011) A blood-based algorithm for the detection of Alzheimer’s disease. Dem Geriatri Cogn Dis 32: 55-62. doi:.
    1. O’Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K et al. (2011) A Blood-Based Screening Tool for Alzheimer’s Disease That Spans Serum and Plasma: Findings from TARC and ADNI. PLOS ONE 6: e28092. doi:. PubMed: .
    1. Hall JR, Edwards M, Barber RC, Johnson LA, Gong G et al. (2012) Higher groundwater selenium exposure is associated with better memory: A Project FRONTIER Study. Neurosci Med 3: 18-25. doi:.
    1. Hall JR, O’Bryant SE, Johnson LA, Barber RC (2012) Depressive symptom clusters and neuropsychological performance in mild Alzheimer’s disease and cognitively normal elderly. Depress Res Treat. doi:.
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr et al. (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dem 7: 263-269. doi:. PubMed: .
    1. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V et al. (1983) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatri Res 17: 37-49.
    1. Randolph C (1998) Repeatable Battery for the Assessment of Neuropsychological Status: Manual. San Antonio: The Psychological Corporation.
    1. Royall D, Mahurin RK, Gray K (1992) Bedside assessment of executive cognitive impairment: The Executive Interview (EXIT). J AM Geriatri Soc 40: 1221-1226.
    1. Duff K, Beglinger LJ, Schoenberg MR, Patton DE, Mold J et al. (2005) Test-Retest Stability and Practice Effects of the RBANS in a Community Dwelling Elderly Sample. J Clin Exp Neuropsychol 27: 565-575. doi:. PubMed: .
    1. Duff K, Humphreys Clark JD, O’Bryant SE, Mold JW, Schiffer RB et al. (2008) Utility of the RBANS in detecting cognitive impairment associated with Alzheimer’s disease: Sensitivity, specificity, and positive and negative predictive powers. Arch Clin Neuropsychol 23: 603-612. doi:. PubMed: .
    1. Stokholm J, Vogel A, Gade A, Waldemar G (2005) The executive interview as a screening test for executive dysfunction in patients with mild dementia. J AM Geriatri Soc 53: 1577-1581. doi:. PubMed: .
    1. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198. doi:. PubMed: .
    1. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Bri J Psychiatry 140: 566-572. doi:.
    1. Steinberg BA, Bieliauskas LA, Smith GE, Ivnik RJ (2005) Mayo’s Older Americans Normative Studies: Age- and IQ-Adjusted Norms for the Trail-Making Test, the Stroop Test, and MAE Controlled Oral Word Association Test. Clin Neuropsychol 19: 329-377. doi:. PubMed: .
    1. Hobson VL, Hall JR, Harvey M, Cullum CM, Lacritz L et al. (2011) An examination of the Boston Naming Test: Calculation of "estimated" 60-item score from 30-and 15-item scores in a cognitively impaired population. Int J Geriatri Psychiatry 26: 351-355. doi:.
    1. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG et al. (2007) Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur JNeurol 14: e1-e26. PubMed: .
    1. Kennard M (1998) Diagnostic markers for Alzheimer’s disease. Neurobiol. Aging 19: 131-132.
    1. Boustani M, Callahan CM, Unverzagt FW, Austrom MG, Perkins AJ et al. (2005) Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med 20: 572-577. doi:. PubMed: .
    1. Cotter VT (2006) Alzheimer’s disease: issues and challenges in primary care. Nurs Clin North Am 41: 83-93. doi:. PubMed: .
    1. Doody R, Ferris S, Salloway S, Meuser TM, Murthy A et al. (2008) Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnestic MCI in the community setting. J AM Geriatri Soc 56(4): 106.
    1. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD et al. (2011) Serotonin signaling is associated with lower amyloid-βlevels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 108: 14968-14973. doi:. PubMed: .
    1. Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I et al. (2010) Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacol 58: 911-920. doi:. PubMed: .
    1. Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE et al. (2012) Cognitive outcomes after sertaline treatment in patients with depression of alzheimer disease. Am J Geriatri Psychiatry 20(12): 1036-1044. doi:. PubMed: .

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera